0.00Open4.20Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV7.82%PremiumJan 17, 2025Expiry Date3.92Intrinsic Value100Multiplier-6DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.85Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Larimar Therapeutics Stock Discussion
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
Thursday, 23rd January at 4:05 pm
• Adolescents receive a weight-based dose equivalent to the 50 mg adult dose
• Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open label extension (OLE) study
• Larimar is continuing to enrol...
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
Monday, 16th December at 7:00 am
• Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study
• Tissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells a...
No comment yet